JP2021503892A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021503892A5 JP2021503892A5 JP2020528052A JP2020528052A JP2021503892A5 JP 2021503892 A5 JP2021503892 A5 JP 2021503892A5 JP 2020528052 A JP2020528052 A JP 2020528052A JP 2020528052 A JP2020528052 A JP 2020528052A JP 2021503892 A5 JP2021503892 A5 JP 2021503892A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- tbm
- cdr
- tumor
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024138929A JP2024161539A (ja) | 2017-11-21 | 2024-08-20 | 腫瘍関連抗原に対する三重特異性結合分子及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762589331P | 2017-11-21 | 2017-11-21 | |
| US62/589,331 | 2017-11-21 | ||
| PCT/US2018/062078 WO2019104075A1 (en) | 2017-11-21 | 2018-11-20 | Trispecific binding molecules against tumor-associated antigens and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024138929A Division JP2024161539A (ja) | 2017-11-21 | 2024-08-20 | 腫瘍関連抗原に対する三重特異性結合分子及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021503892A JP2021503892A (ja) | 2021-02-15 |
| JP2021503892A5 true JP2021503892A5 (https=) | 2023-02-02 |
| JP7542438B2 JP7542438B2 (ja) | 2024-08-30 |
Family
ID=66632159
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020528052A Active JP7542438B2 (ja) | 2017-11-21 | 2018-11-20 | 腫瘍関連抗原に対する三重特異性結合分子及びその使用 |
| JP2024138929A Pending JP2024161539A (ja) | 2017-11-21 | 2024-08-20 | 腫瘍関連抗原に対する三重特異性結合分子及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024138929A Pending JP2024161539A (ja) | 2017-11-21 | 2024-08-20 | 腫瘍関連抗原に対する三重特異性結合分子及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20200362054A1 (https=) |
| EP (1) | EP3713962A4 (https=) |
| JP (2) | JP7542438B2 (https=) |
| KR (1) | KR20200088440A (https=) |
| CN (2) | CN121591910A (https=) |
| AU (2) | AU2018370853A1 (https=) |
| CA (1) | CA3082283A1 (https=) |
| IL (1) | IL274591A (https=) |
| RU (1) | RU2020120411A (https=) |
| WO (1) | WO2019104075A1 (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| KR102211837B1 (ko) | 2013-01-14 | 2021-02-03 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| EP3223907A2 (en) | 2014-11-26 | 2017-10-04 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd38 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| PE20171324A1 (es) | 2014-11-26 | 2017-09-11 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales |
| CN109715663B (zh) | 2016-06-28 | 2022-11-25 | Xencor股份有限公司 | 结合生长抑素受体2的异源二聚抗体 |
| JP2021502100A (ja) | 2017-11-08 | 2021-01-28 | ゼンコア インコーポレイテッド | 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体 |
| CA3096052A1 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| KR102870868B1 (ko) | 2018-06-01 | 2025-10-15 | 노파르티스 아게 | Bcma에 대한 결합 분자 및 이의 용도 |
| JP7489407B2 (ja) | 2019-05-21 | 2024-05-23 | ノバルティス アーゲー | Ｃｄ１９結合分子及びその使用 |
| EP3976098A4 (en) | 2019-05-31 | 2023-01-18 | Zymeworks Inc. | METHOD OF USING A BISPECIFIC ANTIGEN-BINDING CONSTRUCT THAT TARGETS HER2 FOR THE TREATMENT OF BILAGE DUCT CANCER |
| US20230128499A1 (en) * | 2020-03-27 | 2023-04-27 | Novartis Ag | Bispecific combination therapy for treating proliferative diseases and autoimmune diseases |
| CN113527496B (zh) * | 2020-04-16 | 2022-03-04 | 上海洛启生物医药技术有限公司 | 抗Trop2纳米抗体及其应用 |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| CA3187944A1 (en) | 2020-06-22 | 2021-12-30 | Ngm Biopharmaceuticals, Inc. | Lair-1-binding agents and methods of use thereof |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| WO2022042576A1 (zh) * | 2020-08-27 | 2022-03-03 | 盛禾(中国)生物制药有限公司 | 一种多功能融合蛋白及其用途 |
| CR20230229A (es) * | 2020-11-06 | 2023-09-05 | Amgen Res Munich Gmbh | Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada |
| IL302412A (en) * | 2020-11-06 | 2023-06-01 | Novartis Ag | Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies |
| CA3199095A1 (en) * | 2020-11-06 | 2022-05-12 | Novartis Ag | Cd19 binding molecules and uses thereof |
| CN113173991B (zh) * | 2020-12-31 | 2023-03-28 | 北京艺妙神州医药科技有限公司 | 一种抗bcma的抗体及其应用 |
| US11739144B2 (en) | 2021-03-09 | 2023-08-29 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and CLDN6 |
| EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
| CA3219609A1 (en) * | 2021-05-04 | 2022-11-10 | Regeneron Pharmaceuticals, Inc. | Multispecific fgf21 receptor agonists and their uses |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| CN115536749A (zh) * | 2021-06-29 | 2022-12-30 | 三生国健药业（上海）股份有限公司 | 三特异性抗体、其制备方法和用途 |
| CA3227537A1 (en) * | 2021-07-27 | 2023-02-02 | Morphosys Ag | Combinations of antigen binding molecules |
| WO2023064841A1 (en) * | 2021-10-13 | 2023-04-20 | The Wistar Institute Of Anatomy And Biology | Antibodies for use against sars-cov-2 |
| IL313437A (en) * | 2021-12-07 | 2024-08-01 | Scripps Research Inst | Switchable car-t therapies for treating human cancers |
| TW202342549A (zh) * | 2022-03-01 | 2023-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合ｆｌｔ３和ｃｄ３的抗原結合分子及其醫藥用途 |
| CA3254129A1 (en) * | 2022-04-14 | 2023-10-19 | Novartis Ag | DOSAGE REGIMEN FOR ANTI-CD19 AGENTS AND THEIR USES |
| WO2024074145A1 (zh) * | 2022-10-08 | 2024-04-11 | 盛禾(中国)生物制药有限公司 | 一种结合baffr和cd3的双特异性抗体及其应用 |
| CN118420712A (zh) * | 2023-02-01 | 2024-08-02 | 上海健信生物医药科技有限公司 | 一种三特异性抗体技术平台及其应用 |
| TW202434644A (zh) * | 2023-02-07 | 2024-09-01 | 大陸商上海齊魯製藥研究中心有限公司 | 三特異性抗原結合分子及其應用 |
| WO2024173607A2 (en) | 2023-02-14 | 2024-08-22 | Evolveimmune Therapeutics, Inc. | Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment |
| WO2024240064A1 (zh) * | 2023-05-19 | 2024-11-28 | 贝达药业股份有限公司 | 靶向抗原表位多肽的抗体药物偶联物及其应用 |
| WO2024249387A2 (en) * | 2023-05-29 | 2024-12-05 | The Regents Of The University Of California | T cell redirecting bispecific antibodies against cytomegaloviruses |
| AU2024341660A1 (en) | 2023-09-11 | 2026-03-12 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof |
| WO2025064890A1 (en) | 2023-09-20 | 2025-03-27 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof |
| AU2024345039A1 (en) | 2023-09-20 | 2026-03-19 | Evolveimmune Therapeutics, Inc. | Multispecific antibodies that bind cd3 and cd2 and methods of use thereof |
| WO2025080730A1 (en) * | 2023-10-09 | 2025-04-17 | Northwestern University | Tri-specific t cell engager for treatment of glioblastoma |
| WO2025162207A1 (zh) * | 2024-01-31 | 2025-08-07 | 上海复宏汉霖生物技术股份有限公司 | 抗liv1抗体及使用方法 |
| TW202602939A (zh) * | 2024-04-06 | 2026-01-16 | 大陸商華深智藥生物科技（蘇州）有限公司 | 一種多特異性抗體t細胞銜接器 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6764681B2 (en) * | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| US5951983A (en) * | 1993-03-05 | 1999-09-14 | Universite Catholique De Louvain | Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies |
| DE19725586C2 (de) * | 1997-06-17 | 1999-06-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper |
| JP2006526414A (ja) * | 2003-06-02 | 2006-11-24 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 脱免疫化抗ｃｄ３抗体 |
| EP1940881B1 (en) * | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| WO2014025198A2 (ko) * | 2012-08-09 | 2014-02-13 | 주식회사 한독 | Lfa3 변이체 및 상기 변이체 또는 lfa3 cd2 결합영역과 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도 |
| WO2014116846A2 (en) * | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| US20170335281A1 (en) * | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| AU2015244039B2 (en) * | 2014-04-07 | 2021-10-21 | Novartis Ag | Treatment of cancer using anti-CD19 chimeric antigen receptor |
| EP2930188A1 (en) * | 2014-04-13 | 2015-10-14 | Affimed Therapeutics AG | Trifunctional antigen-binding molecule |
| EA035419B9 (ru) * | 2014-05-29 | 2020-08-07 | Мэкроудженикс, Инк. | Триспецифичные связывающие молекулы и способы их применения |
| KR102508023B1 (ko) * | 2014-09-03 | 2023-03-10 | 이뮤노젠 아이엔씨 | 세포-결합제 및 세포독성 약물을 포함하는 콘주게이트 |
| WO2016105450A2 (en) * | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| WO2016146702A1 (en) * | 2015-03-16 | 2016-09-22 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Trispecific binding molecules for treating hbv infection and associated conditions |
| US11667691B2 (en) * | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| WO2017142928A1 (en) * | 2016-02-17 | 2017-08-24 | Macrogenics, Inc. | Ror1-binding molecules, and methods of use thereof |
-
2018
- 2018-11-20 JP JP2020528052A patent/JP7542438B2/ja active Active
- 2018-11-20 US US16/765,830 patent/US20200362054A1/en not_active Abandoned
- 2018-11-20 CN CN202511437832.4A patent/CN121591910A/zh active Pending
- 2018-11-20 KR KR1020207017766A patent/KR20200088440A/ko not_active Withdrawn
- 2018-11-20 CA CA3082283A patent/CA3082283A1/en active Pending
- 2018-11-20 CN CN201880086747.XA patent/CN111601824B/zh active Active
- 2018-11-20 EP EP18880478.5A patent/EP3713962A4/en active Pending
- 2018-11-20 RU RU2020120411A patent/RU2020120411A/ru unknown
- 2018-11-20 WO PCT/US2018/062078 patent/WO2019104075A1/en not_active Ceased
- 2018-11-20 AU AU2018370853A patent/AU2018370853A1/en not_active Abandoned
-
2020
- 2020-05-11 IL IL274591A patent/IL274591A/en unknown
-
2022
- 2022-09-20 AU AU2022235550A patent/AU2022235550A1/en not_active Abandoned
-
2024
- 2024-08-20 JP JP2024138929A patent/JP2024161539A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021503892A5 (https=) | ||
| RU2020120411A (ru) | Триспецифические связывающие молекулы, направленные против опухолеассоциированных антигенов, и пути их применения | |
| JP7438958B2 (ja) | 新規な抗体分子、その調製方法及びその使用 | |
| JP2022093564A5 (https=) | ||
| JP2022511813A5 (https=) | ||
| CN102574926B (zh) | Muc1抗体 | |
| JP2024532485A (ja) | Ｃｄ１３７および腫瘍関連抗原に結合する二重特異性結合タンパク質 | |
| CN113330034A (zh) | 针对B7-H3的IgV结构域的单克隆抗体及其用途 | |
| RU2019123613A (ru) | Биспецифические антигенсвязывающие молекулы, содержащие антитело к4-1вв, клон 20н4.9 | |
| Zhu et al. | Multifunctional receptor-targeting antibodies for cancer therapy | |
| JP2013502913A5 (https=) | ||
| JP2018507188A5 (https=) | ||
| JP2019509055A5 (https=) | ||
| CN115052896A (zh) | 抗ror1抗体和组合物 | |
| JP2022528030A5 (https=) | ||
| US20250034273A1 (en) | Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof | |
| Luo et al. | Design and applications of bispecific heterodimers: molecular imaging and beyond | |
| JP2023546725A5 (https=) | ||
| CA2691075A1 (en) | Treatment of tumors using specific anti-l1 antibody | |
| JP2024001073A5 (https=) | ||
| CN110072892A (zh) | Mg7，高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用 | |
| JP2025508066A (ja) | 目的としたｔ細胞活性化のためのｃｄ２８二重特異性抗体 | |
| JP2024534468A5 (https=) | ||
| CN103025760A (zh) | 人源化egfr抗体 | |
| IL301995A (en) | Cells comprising t cell-antigen couplers and uses thereof |